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Abstract
OBJECTIVES: Valve-sparing root replacement (VSRR) is thought to reduce the rate of thromboembolic and bleeding events compared
with aortic root replacement using a mechanical aortic root replacement (MRR) with a composite graft by avoiding oral anticoagulation.
But as VSRR carries a certain risk for subsequent reinterventions, decision-making in the individual patient can be challenging.
METHODS: Of 100 Marfan syndrome (MFS) patients who underwent 169 aortic surgeries and were followed at our institution since 1995,
59 consecutive patients without a history of dissection or prior aortic surgery underwent elective VSRR or MRR and were retrospectively
analysed.
RESULTS: VSRR was performed in 29 (David n = 24, Yacoub n = 5) and MRR in 30 patients. The mean age was 33 ± 15 years. The mean
follow-up after VSRR was 6.5 ± 4 years (180 patient-years) compared with 8.8 ± 9 years (274 patient-years) after MRR. Reoperation rates
after root remodelling (Yacoub) were signiﬁcantly higher than after the reimplantation (David) procedure (60 vs 4.2%, P = 0.01). The need
for reinterventions after the reimplantation procedure (0.8% per patient-year) was not signiﬁcantly higher than after MRR (P = 0.44) but
follow-up after VSRR was signiﬁcantly shorter (P = 0.03). There was neither signiﬁcant morbidity nor mortality associated with root
reoperations. There were no neurological events after VSRR compared with four stroke/intracranial bleeding events in the MRR group
(log-rank, P = 0.11), translating into an event rate of 1.46% per patient-year following MRR.
CONCLUSION: The calculated annual failure rate after VSRR using the reimplantation technique was lower than the annual risk for
thromboembolic or bleeding events. Since the perioperative risk of reinterventions following VSRR is low, patients might beneﬁt from
VSRR even if redo surgery may become necessary during follow-up.
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INTRODUCTION
Aneurysm of the aortic root is the hallmark feature of Marfan syn-
drome (MFS), an autosomal dominant connective tissue disorder
imposed by mutations in the gene encoding for the extracellular
matrix protein ﬁbrillin-1 [1, 2]. Although patients with MFS exhibit
skeletal, ocular and cardiovascular manifestation, aortic aneurysm
determines mortality in this patient population [3]. In 1968, Hugh
Bentall introduced a technique to replace the aortic root using a
mechanical prosthesis sewn into a Dacron graft. Low morbidity
and mortality rates in MFS patients undergoing elective root
surgery using a modiﬁed Bentall procedure have fostered the
concept of prophylactic aortic root surgery to prevent acute aortic
dissection and its sequelae [4]. When valve-sparing root surgery
(VSRR) was introduced into clinical practice, it was an intriguing
concept for the young Marfan patient population requiring elect-
ive surgery.
But it was soon realized that MFS patients present with an in-
herent weakness of the aortic valve cusps itself that is usually not
seen in other patient populations presenting with aortic root an-
eurysm. Patients frequently present with fenestrations, small tears
at the commissures and elongated free margins. Although one can
argue that this is just the result of stress due to the dilated aortic
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root and enlargement of the annulus which will cease after the
root has been reconstructed, the issue of longevity of VSRR in
MFS persists. This is an important issue in adult patients where a
sufﬁciently large prosthesis can be easily implanted and is ex-
pected to last a lifetime. Therefore, we and others, while embra-
cing VSRR in other patient populations, have been a bit more
cautious in performing this procedure in patients with MFS.
Owing to the almost normal life expectancy of MFS patients in
the current era, the risk for thromboembolic and bleeding events
due to life-long oral anticoagulation following mechanical aortic
root replacement (MRR) is becoming more and more of an issue
and VSRR seems an attractive option to reduce these risks. But as
VSRR carries a certain risk for subsequent reinterventions, decision-
making in the individual patient can be challenging.
AIM
Aim of this study was to investigate the risk of bleeding, thrombo-
embolism and reintervention after VSRR or MRR in MFS patients.
PATIENTS ANDMETHODS
Data from 100 MFS consecutive patients (mean age at initial
surgery 35.6 ± 14 years, range 9–69 years, 59% male patients) ful-
ﬁlling Ghent criteria who underwent 169 major aortic operations
and were followed at this institution since 1995 was retrospective-
ly analysed. Patients who underwent genetic testing and were
FBN1 negative retrospectively underwent TGFBR1 and R1 testing
and those who tested positive were excluded.
For the current study, 59 patients without a history of dissection
or prior aortic surgery who underwent elective VSRR or MRR
could be identiﬁed.
Patients are followed up in our MFS clinics 3, 6 and 12 months
after surgery and then, depending on the ﬁndings, at least once
per year. Patients were evaluated using echocardiography and
ECG-gated, CT angiography to plan surgery, as a follow-up in
patients with dissections and in patients undergoing surgery on
an emergency basis. In benign cases or after uneventful elective
surgery, MR imaging was performed to reduce cumulative radi-
ation exposure.
Furthermore, a phone interview was conducted according to a
standardized questionnaire that was sent to the patients in advance.
Individual informed consent was obtained and patients were asked
if we were allowed to contact their primary care provider regarding
recent developments, changes in medication or CT scans that have
been performed outside our institution. Hereby, a 97% complete-
ness of follow-up was achieved. This study was approved by the
institutional review board and individual informed consent from
the patient or, in case of minors, the parent or the legal guardian
was obtained.
Statistical analysis
Values are given in mean ± SD, when appropriate. In addition to
descriptive statistics, data underwent a Kaplan–Meier survival ana-
lysis, with either aortic reintervention, cerebrovascular event or
death as an event, followed by a log-rank test to compare the
event risk for patients with aortic root replacement by either MRR
or VSRR. Analysis was performed with Stata version 12 software
(StataCorp, College Station, TX, USA).
Indication for surgery
As previously prescribed, since 1995 we have gradually lowered
our threshold to recommend elective aortic root surgery from
initially 50–55 mm until the early 2000s, to 50 mm and now to
45–50 mm in patients suitable for VSRR or progressive dilatation
of more than 5 mm per year [5]. If the aorta at the level of the ino-
minate artery was 35 mm or larger, repair was extended into the
arch by performing a hemi-arch or total arch replacement [6]. If
aortic regurgitation was present and the aortic root size was less
than 45 mm, indication for surgery depended on the extent of
regurgitation and hence left ventricular dimensions. Prophylactic
root replacement was suggested in women wishing to conceive if
the aortic root size exceeded 40 mm [7].
Techniques for aortic root replacement
Aortic root replacement in the MRR group was performed as a
modiﬁed Bentall procedurewith reimplantation of coronary buttons
using a commercially available mechanical composite graft. In
the majority of patients, an SJM mechanical valve (St Jude, St Paul,
MN, USA) in a Gelweave Valsalva vascular prosthesis (Vascutek,
Renfrewshire, UK) was used.
Valve-sparing root replacement (VSRR) was performed in suit-
able candidates using the Yacoub remodelling technique in the
early experience followed by exclusive use of the David reimplan-
tation technique since the late 1990s. We have essentially been
using the David I procedure consistently over the years with ex-
ception of the introduction of the Valsalva graft in the early 2000s.
Reasons not to perform VSRR in patients with MFS were severely
enlarged annuli (>30 mm), bicuspid or pseudo-bicuspid valves
and multiple or large fenestrations of the leaﬂets or partial detach-
ment of the commissures.
Postoperative anticoagulation
After uneventful MRR, patients were started on phenprocoumon
on the 1st postoperative day while a prophylactic dose of unfrac-
tionated heparin (10 000 IU/d) was maintained until target INR
was reached. If patients were not within target range on the 5th
postoperative day, heparin was given in a therapeutic dose. Patients
after VSRR were started on low-dose acetylsalicylic acid on the 1st
postoperative day. Recently, low-dose acetylsalicylic acid for 3
months was added to the regimen in patients with MRR.
RESULTS
Primary aortic root interventions
In 59 patients without a history of dissection or prior aortic
surgery who underwent elective root replacement, VSRR was per-
formed in 29 and MRR in 30 patients. In VSSR, the remodelling
technique was used in 5 patients and the reimplantation technique
in 24. In VSRR, no cusp repairs were performed. Concomitant mitral
valve repair was performed in 2 patients. The mean age in the MRR
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group was 36 ± 12 years compared with 27 ± 12 years (P = 0.004) in
the VSRR group. The mean aortic root size was 48 ± 5.4 mm (40–65
mm) in the VSRR group compared with 54 ± 12 mm (37–90 mm) in
the MRR group (P = 0.014).
Aortic valve regurgitation (none/mild/moderate/severe) was
present in 45/41/14/0% of patients in the VSRR and in 27/27/40/6%
of the MRR group (P = 0.02).
Reinterventions on the aortic root
The mean follow-up after VSRR was 6.5 ± 4 years (180 patient-
years) compared with 8.8 ± 9 years (274 patient-years) after MRR.
Aortic root reoperation rates after the remodelling (Yacoub) pro-
cedure were signiﬁcantly higher than after the reimplantation
(David) procedure [3/5 (60%) vs 1/24 (4.2%), P < 0.0001]. Freedom
from reintervention on the aortic root in VSRR using the remodel-
ling technique at 5, 10 and 15 years was 40% compared with 94%
at 5 years when using the reimplantation approach (Fig. 1).
The mean time to reoperation was 1.6 years in the reimplanta-
tion compared with 3.8 years in the remodelling group. All reinter-
ventions were performed due to progressive aortic valve
insufﬁciency. MRR was performed in 3 patients. In 1 young patient,
ﬁrst aortic valve replacement was performed, followed by MRR 7
years later. There were no reinterventions on the aortic root in
patients after MRR. No patient presented with endocarditis or valve
thrombosis throughout follow-up.
The need for reintervention after the reimplantation procedure
(0.8% per patient-year) was not signiﬁcantly higher than after
MRR (P = 0.44) but follow-up after VSRR was signiﬁcantly shorter
(P = 0.03). There was neither signiﬁcant morbidity nor mortality
associated with root reoperations.
Non-root reinterventions
The only non-root reoperation in the VSRR group was mitral valve
replacement in 1 patient, whereas in the MRR group there was 1
mitral valve replacement, 1 total arch replacement and 1 infrarenal
aortic aneurysm repair. In the VSRR group 2/29 suffered from type B
dissection but none required thoraco-abdominal surgery, whereas
in the MRR group 8/30 experienced type B dissection (P = 0.04) and
5 required thoraco-abdominal aortic replacement.
Bleeding and thromboembolism
There were no neurological nor other bleeding or thrombo-
embolic events after VSRR compared with four stroke/intracranial
bleeding events in the MRR group (log-rank, P = 0.11), translating
into an event rate of 1.46% per patient-year following MRR. The
rate of freedom from cerebrovascular events in the MRR group at
5, 10 and 15 years was 92%, 92 and 83% compared with 100% in
the VSRR group, respectively (Fig. 2). The following cerebrovascu-
lar events were observed: (a) stroke with hemiparesis 12 years
after elective MRR and 8 years after diagnosis of type B dissection.
The patient subsequently recovered except for a residual
hypoaesthesia of the leg and underwent thoraco-abdominal
surgery for progressive dilatation 2 years after the stroke; (b)
chronic subdural haematoma with acute bleeding 1 year after
MRR. The patient developed acute type B dissection 9 years later
and subsequently underwent thoraco-abdominal surgery for
progressive dilatation; (c) stroke with hemiparesis and aphasia
after arch replacement, which was performed 16 years after MRR
and (d) massive intracerebral bleeding 5 days after acute type B
dissection and 5 months after uneventful MRR.
There was 1 patient with pulmonary embolism 1 year after
MRR. The patient developed acute type B dissection 6 years later
and subsequently underwent thoraco-abdominal surgery for
progressive dilatation.
Re-exploration due to bleeding was necessary in 1 patient in
each group. Following MRR, 2 patients developed pericardial
Figure 2: The Kaplan–Meier curve depicting freedom from cerebrovascular
events in patients who underwent either VSRR or MRR. VSRR: valve-sparing
root replacement; MRR: mechanical aortic root replacement.
Figure 1: The Kaplan–Meier curve depicting signiﬁcant differences in freedom
from reintervention on the aortic root in patients undergoing VSRR using the re-
modelling technique compared with the reimplantation technique and MRR.
VSRR: valve-sparing root replacement; MRR: mechanical aortic root replacement.
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effusion. One patient in the VSRR group developed a retrosternal
haematoma and underwent CT-guided drainage. There was no
patient with non-cerebral major haemorrhage or gastrointestinal
bleeding. There was only 1 patient with a minor bleeding event
several days after tooth extraction.
In the VSSR group, 5 (17%) of the patients were discharged with
coumadin due to postoperative atrial ﬁbrillation (recurrent or
longer than 48 h). None of these patients experienced a thrombo-
embolic or bleeding event while being on coumadin.
Mortality
There were no signiﬁcant differences in survival between patients
who underwent MRR or VSRR (log rank, P = 0.41). Overall 30-day,
6-month, 1-year and late mortality rates were 1.7, 3.4, 3.4 and
8.5%, respectively (Fig. 3). Operative mortality in patients requiring
aortic root reintervention after failed VSRR was zero.
There were four deaths in the MRR group compared with one
death in the remodelling and none in the reimplantation group.
Causes of death were (a) massive intracerebral bleeding 5 days
after acute type B dissection and 5 months after uneventful MRR,
(b) malignant arrhythmia during the postoperative course in a
young man with a severe form of MFS and concomitant dilative
cardiomyopathy who underwent aortic root replacement, con-
comitant mitral valve replacement and tricuspid valve repair, (c)
multiorgan failure after non-cardiac surgery 21 years after MRR
and 32 years after mitral valve replacement, (d) aortic rupture
after type B dissection 2 years after uneventful MRR and (e) con-
gestive heart failure complicated by sepsis 13 years after VSRR.
DISCUSSION
Elective root replacement using a tube graft with a mechanical
valve is a safe operation and has contributed to the increased sur-
vival of MFS patients over the past decades [4, 8, 9]. Perioperative
complications are rare and operative mortality has become an ex-
ceptional event. Furthermore, it is a very durable solution; in our
cohort, there was no reoperation on the aortic root. Prosthetic
valve endocarditis is often mentioned but, in our series, there was
no case of endocarditis within the past 20 years.
Several studies with larger patient populations report a low inci-
dence of thromboembolic complications during follow-up. Radu
et al. report on 100 patients after MRR with a mean age of 65
years and an event rate of 3.6 per 100 patient-years [10]. In a large
cohort of patients with 242 mechanical and 64 biological root re-
placement from the Yale group, freedom from bleeding, stroke
and distal embolism was 91% at 10 years [11]. Although these
patients were generally older and had more comorbidities than
most MFS patients, in a study by Karck et al. comparing 74 MRR
and 45 VSRR in MFS patients, 24% of survivors in the MRR group
experienced bleeding or thromboembolic events during follow-
up [12].
In the largest series of MFS patients to date, Cameron et al.
report that among 372 patients, thromboembolism was the most
common late complication after aortic root replacement but only
occurred in patients with MRR. The actuarial rate of freedom from
thromboembolism was 96.3, 93.3, 91.0 and 89.8% at 5, 10, 15 and
20 years, respectively [8].
Although most studies suffer from uneven follow-up, VSRR has
already demonstrated superiority in terms of thromboembolic
events and bleeding. The Hopkins group compared outcomes in
140 MFS patients undergoing either MRR (n = 56) or VSRR
(n = 84). Thromboembolic events were signiﬁcantly more frequent
in the MRR group (9 vs 1%, P = 0.03) but the rate of dissection,
which certainly inﬂuences the thromboembolic rate, was much
higher in the MRR group (16 vs 1%, P = 0.001) [9]. Nevertheless,
other groups report similarly positive results [13, 14].
Unfortunately, most thromboembolic events are associated
with neurological impairment which signiﬁcantly reduces the
quality of life and puts the patients’ ability to lead an autonomous
life at risk. Furthermore, perioperative stroke is, besides congestive
heart and multiorgan failure, also a major determinant in morbid-
ity and mortality in redo aortic surgery. Therefore, in our opinion,
the thromboembolic event rate after MRR has to be compared
with the rate of reintervention after VSRR and the risk associated
with the reintervention itself to allow a balanced decision. To
achieve comparable results, we excluded patients with prior aortic
interventions or patients who initially presented with acute dissec-
tion since these factors are known to increase the thromboembol-
ic event rate.
The reintervention rate after VSRR may certainly be inﬂuenced
by the aggressiveness with which this approach is pursued by
each centre. In our practice, VSRR was adopted very early for chil-
dren but we remained hesitant in the adult population due to the
inherent weakness of the aortic cusp tissue in MFS. Furthermore,
many MFS patients presented at a time when the annulus was
already signiﬁcantly enlarged, the cusp stretched and a durable
repair seemed unlikely. In our series, patients with VSRR had sig-
niﬁcantly smaller root diameters and less aortic regurgitation
compared with those who underwent MRR. The fact that there is
considerable overlap indicates the importance of other para-
meters. Although some surgeons expressed their views that MFS
itself is not a risk factor of VSRR failure anymore [13], a large inter-
national registry from the Aortic Valve Operative Outcomes in
Marfan Patients Study Group found that the outcome of VSRR in
MFS is mostly likely different from that in non-MFS patients [15].
After including 316 MFS patients from experienced centres, 7% of
Figure 3: The Kaplan–Meier curve showing no signiﬁcant differences regarding
survival in patients who underwent either elective MRR or VSRR. VSRR: valve-
sparing root replacement; MRR: mechanical aortic root replacement.
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VSRR patients had developed grade 2 AR after the ﬁrst year, which
is a worse outcome compared with non-MFS patient populations.
Although, over the past decade, VSRR has certainly become
the method of choice in young MFS patients in our centre, we still
do not take the possibility of failure lightly and maintain a rather
conservative approach. Despite the increasing awareness for con-
nective tissue disease, many patients are only diagnosed at a point
when the aortic root size already far exceeds the recommended
threshold for intervention, thereby limiting the possibility of
sparing the valve.
In the current analysis, the annual failure rate of VSRR is actually
lower than the risk for a thromboembolic event or stroke. Obviously,
this analysis is severely limited by the low occurrence rate of both
events, but is similar to results from a large meta-analysis that ana-
lysed 11 observational studies reporting valve-related morbidity
and mortality after MRR or VSRR in patients with MFS and a study
size of n>30 to reﬂect the centre’s experience [16]. In this analysis,
including 1385 MFS patients, the thromboembolic event rate was
0.7% per year after MRR compared with 0.3% per year after VSRR.
Reintervention rates were signiﬁcantly higher in the VSRR group
compared with the MRR group (0.3/year vs 1.3%/year). But when
looking only at the subgroup of patients who underwent VSRR
using the reimplantation technique, the annual failure rate equals
the thromboembolic event rate of 0.7% per year after MRR. Out-
comes after VSRR depend on patient characteristics, surgical skill
and aggressiveness with which the approach is pursued. There-
fore, to be able to make an informed decision, the surgeon and
the patient have to consider the expected failure rate after VSRR
and compare it with the rate of thromboembolic events after
MRR, which may also vary according to patients’ characteristics in
each centre.
CONCLUSION
In the current study, the calculated annual failure rate after VSRR
using the reimplantation technique was lower than the annual risk
for thromboembolic or bleeding events. As the perioperative risk
of reinterventions following VSRR is low, the patient might beneﬁt
from VSRR even if redo surgery may become necessary during
follow-up.
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APPENDIX. CONFERENCE DISCUSSION
Scan to your mobile or go to
http://www.oxfordjournals.org/page/6153/1
to search for the presentation on the EACTS library
Dr D. Cameron (Baltimore, MA, USA): Dr Schoenhoff, thank you very much for
this beautiful presentation which sheds more light on the debate between
Bentall and valve-sparing procedures for Marfan aortic root aneurysms.
The study shows that both of these surgical approaches have very low opera-
tive risk and that survival out to ten years is virtually identical. You’ve also
shown, as others have, that the remodelling operation is not a good operation
for Marfan syndrome because it does not stabilize the annulus and predisposes
to late aortic regurgitation.
You’ve also shown that the Achilles heel of the Bentall is the continuing but
low risk of thromboembolic complications, and the Achilles heel of the valve-
sparing is the risk for reoperation for aortic regurgitation. But, importantly,
you’ve quantiﬁed those risks which are actually very low, about 1% per year,
slightly higher for the risk of thromboembolism in Bentall, slightly less for the
risk with valve-sparing. But they’re both low at the end of ten years, patients es-
sentially have a low risk of either complication and so are being asked to ‘pick
their poison’, whether they would rather have a reoperation or a stroke. Most
would rather have a reoperation.
There are some limits of the study. Of course, your follow-up is less than ten
years, so it’s not really a long-term follow-up. And most of your Bentalls were in
the early part of the series, so there is historical bias.
We at Johns Hopkins have done a similar analysis of our experience and have
found nearly identical results, which I ﬁnd very encouraging. I want to point out
some remarkable aspects of the clinical care that you provided. You had no epi-
sodes of prosthetic valve endocarditis in the Bentalls over the last 20 years. That
shows again that the standard has been set very high by the Bentall procedure.
You have also had no operative mortality in any patients, even the root
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reoperations. You have set the bar very high for root surgery in Marfan
syndrome.
I have three questions. The most provocative ﬁnding of this study was a sig-
niﬁcantly higher risk of distal aortic dissection in the mechanical valve Bentall
patients compared to valve-sparing, which suggests that the mechanical valve
may impart more stress on the descending aorta. Could you to comment on
that?
I also want to ask you to comment on why you think your risk of prosthetic
endocarditis is so low. It may speak to the close follow-up you provide your
patients.
Finally, who does not get a valve-sparing at your centre now? Are issues like
ventricular function and concurrent mitral disease ﬁgured in? How do you
decide for whom the valve-sparing is not really the right operation?
Dr Schoenhoff: Indeed, there is a higher risk for type B dissection in patients
after mechanical root replacement. At the 2013 meeting of the American Heart
Association, we presented data that tried to answer the question of whether a
patient with a proximal repair has a higher risk for subsequent type B dissec-
tion, which was not the case. But at that time, we didn’t differentiate between
valve-sparing and mechanical root replacement.
When we reanalyzed the data for this manuscript, we became aware that
there is a signiﬁcant difference. I think the easy answer would be to say that
MFS patients undergoing an elective Bentall procedure have a more severe
phenotype, and this is why they’re more likely to suffer from type B dissection.
But I’m not sure if that is actually the case. Maybe after all, as you suggested, it’s
the fact that we implant a mechanical valve which has a different ﬂow pattern,
which results in more shear stress for the downstream aorta. But I will certainly
look into that in the near future.
And regarding the thromboembolic event rate?
Dr Cameron: Yes. The thromboembolic rate was actually a little higher than
in other series. But your prosthetic valve endocarditis rate was much less. Could
you comment on that?
Dr Schoenhoff: Regarding the thromboembolic event rate, I think that due to
the small numbers, one event more or less changes percentages quite substan-
tially. If you look at other series, such as the Hannover series with 75 mechanic-
al root replacements and 45 valve-sparing, among the survivors, 24% of
patients had some form of thromboembolic events. And in your own series of
140 Marfan patients, you had an overall thromboembolic event rate of 9%. In
the largest study to date, a meta-analysis published in Heart 2011 with 1400
patients, the event rate was roughly 1% per year, so I think we are not that far
apart.
Regarding endocarditis, I have no idea why that is the case. I also noticed
that in your series, you have several patients that came in with a thrombosed
valve. This is also something we haven’t seen. I think maybe we care for a slight-
ly different patient population in Switzerland. It’s a small country. Most patients
have their primary care provider whom they regularly see and check their
anticoagulation. If there is anything that is slightly abnormal, they are referred
to their cardiologist or we see them in our outpatient clinic. So there might be
a little bit closer follow-up. Other than that, I have no idea why that is because
of the endocarditis.
And regarding your last question?
Dr Cameron:Who doesn’t get a valve-sparing?
Dr Schoenhoff: I think that Dr Carrel, that our department still has a fairly
conservative approach towards valve-sparing in the Marfan patients. I think this
is justiﬁed.
As you can see, just recently, the Aortic Valve Operative Outcomes in Marfan
Patients study was published, and it showed that 7% of patients had grade II
aortic regurgitation after one year. These were all expert centres, and I think
this is much more than you would expect in a non-Marfan population. So I
think it’s justiﬁed to be a little bit more restrictive.
I think that we would not necessarily be inclined to perform a valve-sparing
in a patient who already has a very severely enlarged annulus or in a patient
who has large, thin, stretched cusps with multiple fenestrations and/or partial
detachment of the commissures. Moreover, I think we would be careful in a
patient with a very asymmetrical sinus.
With regard to bicuspid valves, if it’s a very symmetrical valve, we might try,
but if it’s asymmetric and has some calciﬁcation, I think we would rather go for
the Bentall procedure.
Dr T. Sioris (Tampere, Finland): Did some of them receive cusp reinforcement
or cusp plication, free-edge reinforcement with Gore-Tex or suture or cusp
plication?
Dr Schoenhoff: So whenever the need arises to perform extensive cusp
repair or to correct for any major asymmetries, I think we would choose rather
to do a Bentall procedure. And in this series, as far as I know, there was no
reinforcement of the free margin in any patient.
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